相关实验视频

Updated: Jul 28, 2026

Dynamic Contrast Enhanced Magnetic Resonance Imaging of an Orthotopic Pancreatic Cancer Mouse Model

Dynamic Contrast Enhanced Magnetic Resonance Imaging of an Orthotopic Pancreatic Cancer Mouse Model

Published on: April 18, 2015

多参数[⁶⁸Ga]Ga-DOTA-FAPI-04 PET/MR成像生物标志物的预后值,用于晚期胰腺癌患者

Zeyu Zhang¹, Shiwei Guo², Weiwei Su^1,3

¹Department of Nuclear Medicine, Changhai Hospital, Naval Medical University, 168 Changhai Road, Yang Pu District, Shanghai, 200433, China.

European journal of nuclear medicine and molecular imaging

|September 9, 2025

概括

[⁶⁸Ga]Ga-DOTA-FAPI-04 PET/MRI生物标志物,包括明显扩散系数 (ADC) 和全瘤总损伤纤维细胞激活蛋白表达 (W-TLF),可以预测晚期胰腺癌患者的生存率. 较高的W-TLF表明预后较差,这表明纤维细胞活动会影响结果.

科学领域:

在瘤学瘤学.
放射学放射学是一门学科.
医疗成像医学成像

背景情况:

胰腺癌是一种具有不良预后的侵略性恶性瘤.
准确预测无进展生存期 (PFS) 和总生存期 (OS) 对于治疗规划至关重要.
需要新的成像生物标志物来提高预后准确性.

研究的目的:

调查[Ga]Ga-DOTA-FAPI-04 PET/MR成像生物标志物是否可以预测晚期胰腺癌患者的PFS和OS.
为了确定生存的独立成像预测因素.

主要方法:

在一线化疗前,对51名晚期胰腺癌患者进行[68]Ga-DOTA-FAPI-04 PET/MR的回顾性分析.
评估成像生物标志物,包括明显扩散系数 (ADC),标准化吸收值 (SUVmax,SUVmean),纤维细胞激活蛋白-阳性瘤体积 (FTV,W-FTV) 和总损伤FAP表达 (TLF,W-TLF).
使用Kaplan-Meier分析和Cox比例危险模型来评估生物标志物与生存结果之间的关联.

主要成果:

全瘤全损伤FAP表达 (W-TLF) 是PFS (P < 0.001) 和OS (P < 0.05) 的显著独立预测因子.
在多变量分析中,瘤长度,ADC和W-TLF被确定为OS的独立预测因子 (P < 0.05).
在患有阻塞性胰腺炎的小组中,W-TLF和远端FAP阳性吸收体积 (D-FTV) 是OS的独立预测因素 (P <0.05).

结论:

[⁶⁸Ga]Ga-DOTA-FAPI-04 PET/MRI生物标志物,特别是ADC和W-TLF,与晚期胰腺癌中的PFS和OS有关.
这些生物标志物可以作为独立的风险因素,突显纤维细胞活动和炎症在生存中的作用.
这些发现支持这些生物标志物在指导临床试验和个性化胰腺癌治疗策略方面的潜力.

关键词:

纤维细胞激活蛋白质的激活蛋白质聚乙烯 (PET) /MR (MR) 是一种胰腺癌是一种胰腺癌.预测预后预测预测 [68Ga]Ga-DOTA-FAPI-04 的时间表

更多相关视频

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

An Automated Radiosynthesis of [⁶⁸Ga]Ga-FAPI-46 for Routine Clinical Use

Published on: May 24, 2024

相关概念视频

Positron Emission Tomography

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...

Radiological Investigation III: Pulmonary Angiogram and PET Scan

Radiological Investigation III: Pulmonary Angiogram and PET Scan

Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET